1 Min Read
May 8 (Reuters) - Rxi Pharmaceuticals Corp:
* RXI PHARMACEUTICALS - GRANTED PATENT FROM USPTO FOR METHODS OF USE OF SD-RXRNAS TARGETING CONNECTIVE TISSUE GROWTH FACTOR TO TREAT FIBROTIC DISORDERS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.